← Eichor
Condition: Severe Hemophilia A Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Severe Hemophilia A

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Pr
Phase 4 · 2 location(s) · Sanofi · NCT06145373A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265)
Phase 1/Phase 2 · 44 location(s) · Regeneron Pharmaceuticals · NCT06379789Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Phase 4 · 18 location(s) · Octapharma · NCT05935358Liver Biopsy In Haemophilia Gene Therapy
NA · 1 location(s) · University College, London · NCT04817462A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Phase 1/Phase 2 · 2 location(s) · Hoffmann-La Roche · NCT07226206Long-term Anticoagulation in a Patient With Severe Hemophilia A
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07314983Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
Phase N/A · 1 location(s) · Christoph Königs · NCT05802836Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
Phase 3 · 19 location(s) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. · NCT07684898Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
Phase 3 · 21 location(s) · Swedish Orphan Biovitrum · NCT06716814Pharmacokinetic-guided Dosing of Emicizumab
Phase 4 · 8 location(s) · Kathelijn Fischer · NCT06320626Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
Phase 3 · 28 location(s) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. · NCT06142552A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A
Phase N/A · 1 location(s) · Tri-Service General Hospital (TSGH) · NCT05981274Multidimensional Assessment of Chronic Pain in Severe Haemophilia A
Phase N/A · 1 location(s) · Investigación en Hemofilia y Fisioterapia · NCT07096349Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VII
Phase N/A · 10 location(s) · Wayne State University · NCT05022459A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With
Phase 1/Phase 2 · 14 location(s) · Hoffmann-La Roche · NCT05987449Hemophilia A Research Program
Phase N/A · 1 location(s) · University of Washington · NCT07414511A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Phase 1 · 7 location(s) · Pfizer · NCT06703606Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07437404Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
Phase 3 · 24 location(s) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. · NCT07663903ASC618 Gene Therapy in Hemophilia A Patients
Phase 1/Phase 2 · 1 location(s) · ASC Therapeutics · NCT04676048Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Phase 1 · 12 location(s) · Bleeding and Clotting Disorders Institute Peoria, Illinois · NCT05500807A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Phase 3 · 34 location(s) · Pfizer · NCT05611801Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Phase 3 · 75 location(s) · Pfizer · NCT05145127Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
Phase N/A · 4 location(s) · Washington Institute for Coagulation · NCT04131036
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.